Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor combined with S-1 after radical resection for advanced gallbladder cancer
ChiCTR1900022707Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in gallbladder cancer, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: 1-year disease-free survival rate. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
tegafur
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on ChiCTR1900022707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022707.